BioAtla Investor Presentation Deck

Phase 2 CAB-AXL (BA3011): Treatment Emergent Adverse Events (Non-Squamous NSCLC) Any grade (≥15% of patients) OR grade ≥3* (≥3% of patients) in the study population TEAES of any grade, n (%) 14 (35.0) 10 (25.0) 9 (22.5) 9 (22.5) 8 (20.0) 8 (20.0) 7 (17.5) 7 (17.5) 6 (15.0) 6 (15.0) 5 (12.5) Preferred term Fatigue Diarrhea Constipation Decreased appetite Anemia Nausea Peripheral neuropathy Increased AST Dyspnea Neutropenia Increased ALT *No grade 4+ TEAES among most frequent bicatla Rotow J, Dy GK, Camidge DR. Poster presented at: International Association for the Study of Lung Cancer 2023 North America Conference on Lung Cancer; December 1-3, 2023; Chicago, IL. Data Cut Date: 30Jun23 TEAES of grade 3, n (%) 1 (2.5) 1 (2.5) 0 1 (2.5) 2 (5.0) 0 1 (2.5) 3 (7.5) 2 (5.0) 2 (5.0) 3 (7.5) BioAtla| Overview 38

View entire presentation